Vesta late Wednesday posted adjusted earnings of 18 cents a share, up from a loss of 32 cents a year ago as the company's three main lines - property casualty, auto underwriting and life insurance - showed profits.
#Tessera therapeutics stock trial#
Separately, the company's shares climbed as much as 26 percent in after the Birmingham, Ala.-based insurer reported a swing to a profit on continued operations in the third quarter from a loss a year ago. Tomorrows Movement Prediction Forecast & share price targets for tomorrow -TSRA Tessera Technologies, Inc. Read here all the stock news, interviews and trial updates from Tessera Therapeutics posted by CRISPR Medicine News. Said it intends to sell part of its non-standard agency and underwriting business through an initial public offering in early 2004. LSI may distribute shares of the storage systems business in a tax-free transaction to its shareholders, or it may sell part of the company in an IPO. The company is weighing an IPO in the first half of 2004. Iron sulfur clusters are essential universal prosthetic groups which can be formed inorganically but, in biology, are bound to proteins and produced. Severino currently serves as Chief Executive Officer of Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology which consists of. Since completing his PhD at the University of Melbourne and Mental Health Research Institute in 2012 he has been a senior. His initial focus was on unravelling the complex biology of the rare childhood genetic disorder Menkes disease. LSI Logic's storage business rang up $104 million in revenue in the third quarter, or 23 percent of the company's total sales. Mark has over 25 years of research experience as a cell biologist in the fields of neuroscience and genetics. The move will allow each operation to focus exclusively on its key product lines. LSI Logic eyes IPOĮnded 10 percent higher at $10.14 after the tech firm set plans to spin off its storage systems business in a possible initial public offering next year. Tessera reported net income of $6.3 million and revenue of $18 million in the first nine months of 2003, compared with net income of $4.2 million and revenue of $12.1 million in the year-ago period.
specialist in chip packaging technology is raising $97.5 million by offering 7.5 million shares with underwriter Lehman Brothers.
#Tessera therapeutics stock plus#
Tessera is generating a strong following partly because it's a player in the hot tech sector, plus it's already profitable. Debuted on Wednesday with a gain and LECG Corp.
0 kommentar(er)
